Observes safety of zolbetuximab in South Korean people with stomach or junction cancer
Collects safety information on zolbetuximab in South Korean people with advanced stomach cancer.
Key facts
- Who runs it
- Astellas Pharma Korea, Inc.
- Where
- Daejeon, Goyang-si, Hwasun Gun, Seoul, Suwon, Uijeongbu-si, and Yangsan, South KoreaSee the 15 sites
- Trial code
- Registry title
- A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
- Status
- Recruiting
- People taking part
- 377 people, planned
- Started
- 3 Apr 2025
- Expected to end
- 31 Jul 2030
- Type of study
- Observational
- Treatments tested
- zolbetuximab
- Record updated
- 22 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people in South Korea with gastric or gastroesophageal junction cancer who are treated with VYLOY (zolbetuximab) under its approved local label. The cancer is locally advanced and cannot be removed by surgery, or has spread.
- Sex
- All sexes can join.
- Disease stage
- Locally advanced cancer that cannot be removed by surgery, or cancer that has spread (metastatic), of the stomach or where the food pipe joins the stomach.
Main reasons for not taking part
- Any reason VYLOY cannot be used, according to the approved local label.
- Being registered, or scheduled to be registered, in a clinical trial that gives an investigational drug.
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Patients who receive treatment with VYLOY injection, according to the approved local label
Who cannot take part
- Patients who are registered or scheduled to be registered in any clinical trials involving investigational drug administration
- Patients with any contraindication for VYLOY injection, according to the approved local label
Where in South Korea
- DaejeonHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- Goyang-si, Gyeonggi-doHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- Hwasun Gun, Jeollanam-doHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- SeoulHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- SeoulHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- SeoulHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- SeoulHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- SeoulHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- SeoulHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- SeoulHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- SeoulHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- Suwon, Gyeonggido [Kyonggi-do]Hospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- Suwon, Gyeonggi-doHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- Uijeongbu-si, Gyeonggi-doHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- Yangsan, Gyeongsangnam-doHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
About the trial
What the trial wants to find out
This study is for people in South Korea who have cancer in or around the stomach (gastric cancer) or cancer where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Their cancer is locally advanced, unresectable, or metastatic. Locally advanced means the cancer has spread to tissue close by. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body.
Read full original descriptionShow less
In South Korea, VYLOY is approved for the treatment of gastric cancer or GEJ cancer. The people in this study will receive VYLOY as part of their usual treatment for their cancer. In standard clinical practice VYLOY is given to people slowly through a tube into a vein.
The main aim of the study is to collect information in a real-world setting about the safety of VYLOY in people with gastric cancer or GEJ cancer in clinics in South Korea. This study will also help researchers learn how long people's gastric cancer or GEJ cancer stays stable.
This study is about collecting information only. This is known as an observational study. The individual's doctor decides on treatment, not the sponsor (Astellas). The study will last about 1 year (54 weeks).
The group in the trial
- Vyloy
Patients who receive treatment with Vyloy injection 100 mg or 300 mg (zolbetuximab), according to the approved local label.
Treatment: zolbetuximab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Post-marketing Observational Study of VYLOY (Zolbetuximab) Injection 100 mg, 300 mg for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma in South Korea
- Plain-language title
- Observes safety of zolbetuximab in South Korean people with stomach or junction cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 22 October 2026